


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO AGREEMENT FOR ACQUISITION OF
AN ANTI-LAG3 MONOCLONAL ANTIBODY

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that on 18 May 2022, Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“**CTTQ**”), a subsidiary of the Company, has entered into a definitive agreement with Symphogen A/S (“**Symphogen**”), acquiring the Sym022 programme, an anti-LAG3 monoclonal antibody (the “**Product**”). Symphogen is a wholly-owned subsidiary of Servier, a global independent pharmaceutical company, and is Servier’s Antibody Center of Excellence.

The Product is a recombinant, fully human effector-function attenuated anti-LAG-3 monoclonal antibody which has shown significant tumour growth inhibition potential in the pre-clinical stage. The Product has completed two phase 1 clinical trials and the results show it is safe and well-tolerated both as a monotherapy and in combination with other checkpoint inhibitors.

The acquisition of the Product has the following strategic significance to the Group:

1. Strengthen our oncology pipeline with a clinically validated immuno-oncology target;
2. Strategic opportunity to expand our combination therapies with our marketed products such as anlotinib and penpulimab, and clinical assets such as TQB2450 (anti-PD-L1 inhibitor) and TQB2618 (anti-TIM3 inhibitor); and
3. Support our globalization plans by adding an asset with global rights and completed global phase 1 studies to our pipeline.

CTTQ will pay to Symphogen a purchase price at closing as well as potential sales-related payments.

The transaction is subject to closing conditions and is expected to complete in June 2022. The sale of the Product was managed by Results Healthcare.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 18 May 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.